Classic diabetic ketoacidosis and the euglycemic variant: Something old, something new
Authors:
Open Access
- 2 January 2025
- journal article
- review article
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 92 (1) , 33-39
Abstract
Diabetic ketoacidosis (DKA) was historically considered a condition typical of type 1 diabetes. However, patients with type 2 diabetes may present with DKA, usually with higher blood glucose levels and milder ketoacidosis. With the increased use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, the variant euglycemic DKA has been described. SGLT-2 inhibitors cause a low level of ambient ketones; any additional ketone formation predisposes to ketoacidosis, while the agent’s glycosuric effect limits hyperglycemia. The principles of DKA management are fluid administration, electrolyte control, and glucose control with insulin. In euglycemic DKA, the immediate use of a glucose-containing intravenous fluid induces endogenous insulin secretion and stops ketogenesis. Due to the half-life of SGLT-2 inhibitors, the duration of euglycemic DKA may be more prolonged.Keywords
This publication has 21 references indexed in Scilit:
- What are we waiting for? A review of early basal insulin therapy in diabetic ketoacidosis managementThe American Journal of Emergency Medicine, 2023
- Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetesMedicine, 2023
- The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting systemNutrition, Metabolism and Cardiovascular Diseases, 2022
- Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?Diabetes, Obesity and Metabolism, 2021
- Clinical Effects of Balanced Crystalloids vs Saline in Adults With Diabetic KetoacidosisJAMA Network Open, 2020
- Adverse effects of SGLT2 inhibitors on bone healthNature Reviews Nephrology, 2018
- Utility of Initial Bolus Insulin in the Treatment of Diabetic KetoacidosisThe Journal of Emergency Medicine, 2010
- Hyperglycemic Crises: Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar State (HHS)2008
- Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patientsInternational Journal Of Clinical Practice, 2006
- Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosisThe American Journal of Medicine, 2004